The organ transplant immunosuppressant drugs market size has grown steadily in recent years. It will grow from $5.35 billion in 2024 to $5.52 billion in 2025 at a compound annual growth rate (CAGR) of 3.2%. The growth in the historic period can be attributed to increased transplant procedures, improved healthcare infrastructure, research and development, a global aging population, and increasing awareness.
The organ transplant immunosuppressant drugs market size is expected to see steady growth in the next few years. It will grow to $6.61 billion in 2029 at a compound annual growth rate (CAGR) of 4.6%. The growth in the forecast period can be attributed to emerging therapies, rising incidence of organ failures, personalized medicine, global health initiatives, and international collaboration. Major trends in the forecast period include technological innovations, technological advancements, cost containment strategies, market consolidation and partnerships, and increasing organ transplants.
The growing demand for organ transplantation is expected to enhance the organ transplant immunosuppressant drugs market. Organ transplantation involves surgically replacing a diseased or damaged organ in a person’s body with a healthy organ from a donor. This life-saving procedure is crucial for replacing failed organs, and immunosuppressant drugs play a vital role in preventing the rejection of transplanted organs, which can result in organ failure. The availability and effectiveness of these drugs are critical to the success of transplantation. For example, in 2023, the Organ Procurement and Transplantation Network (OPTN), a U.S.-based public-private partnership, reported that approximately 16,335 individuals donated one or more organs after their passing. This marks the first year with over 15,000 deceased donors, reflecting a 9.6% increase from 2022. Thus, the rising demand for organ transplantation is driving growth in the organ transplant immunosuppressant drugs market.
The expanding geriatric population is projected to fuel the growth of the organ transplant immunosuppressant drugs market. Immunosuppressants are crucial for elderly transplant recipients, necessitating tailored drug regimens to prevent rejection while mitigating potential adverse effects and drug interactions. By 2030, the World Health Organization estimates that 1 in 6 people worldwide will be aged 60 or older, reaching 1.4 billion, doubling to 2.1 billion by 2050. This demographic shift underscores the market's growth driven by the expanding geriatric populace.
Product innovation is a significant trend in the organ transplant immunosuppressant drugs market. Major companies in this sector are concentrating on developing innovative solutions, such as combination therapies, to maintain their competitive edge. Combination therapy, which utilizes two or more immunosuppressant drugs, is becoming increasingly common as it can offer enhanced immunosuppression while minimizing the risk of side effects. For example, in March 2024, Johnson & Johnson, a U.S.-based pharmaceutical and biotechnology firm, received approval from the U.S. Food and Drug Administration (FDA) for OPSYNVI. This single-tablet combination is designed for the long-term management of pulmonary arterial hypertension (PAH) and includes tadalafil, a phosphodiesterase 5 (PDE5) inhibitor, and macitentan, an endothelin receptor antagonist (ERA). OPSYNVI can be prescribed to patients with PAH who are either new to treatment or currently using an ERA, PDE5 inhibitor, or both. Additionally, patients who are taking consistent doses of macitentan 10 mg and tadalafil 40 mg (20 mg x 2) as separate tablets may be switched to OPSYNVI.
Market leaders in the organ transplant immunosuppressant drugs sector prioritize advanced drug solutions to augment their product portfolios and meet patient needs. Advanced medications aim to modulate the immune system in transplant recipients. For instance, in August 2023, Strides Pharma Science Ltd. secured USFDA approval for Cyclosporine Softgel Capsules USP (Modified), catering to kidney, liver, and heart transplant recipients. This approval reinforces Strides' position in the immunosuppressant market, complementing their existing offerings and enhancing patient care outcomes.
In January 2022, CareDx, Inc., a U.S.-based precision medicine company, acquired The Transplant Pharmacy for an undisclosed amount. This acquisition allows CareDx, Inc. to enhance its medication management portfolio, particularly in the area of organ transplantation. The Transplant Pharmacy specializes in providing transplant services at various locations, delivering personalized patient care that includes online patient portal services and a mobile app for medication management.
Major companies operating in the organ transplant immunosuppressant drugs market include Astellas Pharma Inc., F. Hoffmann-La Roche AG, Novartis AG, Accord Healthcare Limited, GlaxoSmithKline PLC, Pfizer Inc., Sanofi S.A., Alsachim a Shimadzu Group Company, Neovii Pharmaceuticals AG, Zydus Lifesciences Limited, Dr. Reddy's Laboratories Ltd., Lupin Limited, Mylan N.V., Strides Pharma Global Pte Ltd., Asahi Kasei Corporation, Bristol-Myers Squibb Company, Veloxis Pharmaceuticals A/S, Viatris Inc., Janssen Pharmaceuticals Inc., AbbVie Inc., Hansa Biopharma AB, Wockhardt Ltd, Glenmark Pharmaceuticals Ltd., Biocon Ltd., Hikma Pharmaceuticals PLC, Teva Pharmaceutical Industries Ltd., Cipla Ltd., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Intas Pharmaceuticals Limited, Alkem Laboratories Limited, Torrent Pharmaceuticals Limited.
North America was the largest region in the organ transplant immunosuppressant drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the global organ transplant immunosuppressant drugs market report during the forecast period. The regions covered in the organ transplant immunosuppressant drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the organ transplant immunosuppressant drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Organ transplant immunosuppressant drugs are crucial medications employed to curb the immune response in transplant recipients, mitigating the risk of rejection against the transplanted organ.
These drugs primarily fall into several classes calcineurin inhibitors, antiproliferative agents, mTOR inhibitors, steroids, and other miscellaneous classes. Calcineurin, an enzyme pivotal in T-cell activation, prompts the immune system to attack transplanted organs. Calcineurin inhibitors serve to prevent such rejection reactions in patients undergoing organ transplantation. These drugs find extensive use in heart, kidney, liver, lung, pancreas, and other organ transplants, and they are typically dispensed through hospital pharmacies, retail outlets, and online pharmacy platforms.
The organ transplant immunosuppressant drugs market research report is one of a series of new reports that provides organ transplant immunosuppressant drugs market statistics, including organ transplant immunosuppressant drugs industry global market size, regional shares, competitors with an organ transplant immunosuppressant drugs market share, detailed organ transplant immunosuppressant drugs market segments, market trends and opportunities, and any further data you may need to thrive in the organ transplant immunosuppressant drugs industry. This organ transplant immunosuppressant drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The organ transplant immunosuppressant drugs market consists of sales of drugs such asteroid-sparing immunosuppressants, prednisone, antineoplastics, monoclonal antibody drug, and immunosuppressive agents. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The organ transplant immunosuppressant drugs market size is expected to see steady growth in the next few years. It will grow to $6.61 billion in 2029 at a compound annual growth rate (CAGR) of 4.6%. The growth in the forecast period can be attributed to emerging therapies, rising incidence of organ failures, personalized medicine, global health initiatives, and international collaboration. Major trends in the forecast period include technological innovations, technological advancements, cost containment strategies, market consolidation and partnerships, and increasing organ transplants.
The growing demand for organ transplantation is expected to enhance the organ transplant immunosuppressant drugs market. Organ transplantation involves surgically replacing a diseased or damaged organ in a person’s body with a healthy organ from a donor. This life-saving procedure is crucial for replacing failed organs, and immunosuppressant drugs play a vital role in preventing the rejection of transplanted organs, which can result in organ failure. The availability and effectiveness of these drugs are critical to the success of transplantation. For example, in 2023, the Organ Procurement and Transplantation Network (OPTN), a U.S.-based public-private partnership, reported that approximately 16,335 individuals donated one or more organs after their passing. This marks the first year with over 15,000 deceased donors, reflecting a 9.6% increase from 2022. Thus, the rising demand for organ transplantation is driving growth in the organ transplant immunosuppressant drugs market.
The expanding geriatric population is projected to fuel the growth of the organ transplant immunosuppressant drugs market. Immunosuppressants are crucial for elderly transplant recipients, necessitating tailored drug regimens to prevent rejection while mitigating potential adverse effects and drug interactions. By 2030, the World Health Organization estimates that 1 in 6 people worldwide will be aged 60 or older, reaching 1.4 billion, doubling to 2.1 billion by 2050. This demographic shift underscores the market's growth driven by the expanding geriatric populace.
Product innovation is a significant trend in the organ transplant immunosuppressant drugs market. Major companies in this sector are concentrating on developing innovative solutions, such as combination therapies, to maintain their competitive edge. Combination therapy, which utilizes two or more immunosuppressant drugs, is becoming increasingly common as it can offer enhanced immunosuppression while minimizing the risk of side effects. For example, in March 2024, Johnson & Johnson, a U.S.-based pharmaceutical and biotechnology firm, received approval from the U.S. Food and Drug Administration (FDA) for OPSYNVI. This single-tablet combination is designed for the long-term management of pulmonary arterial hypertension (PAH) and includes tadalafil, a phosphodiesterase 5 (PDE5) inhibitor, and macitentan, an endothelin receptor antagonist (ERA). OPSYNVI can be prescribed to patients with PAH who are either new to treatment or currently using an ERA, PDE5 inhibitor, or both. Additionally, patients who are taking consistent doses of macitentan 10 mg and tadalafil 40 mg (20 mg x 2) as separate tablets may be switched to OPSYNVI.
Market leaders in the organ transplant immunosuppressant drugs sector prioritize advanced drug solutions to augment their product portfolios and meet patient needs. Advanced medications aim to modulate the immune system in transplant recipients. For instance, in August 2023, Strides Pharma Science Ltd. secured USFDA approval for Cyclosporine Softgel Capsules USP (Modified), catering to kidney, liver, and heart transplant recipients. This approval reinforces Strides' position in the immunosuppressant market, complementing their existing offerings and enhancing patient care outcomes.
In January 2022, CareDx, Inc., a U.S.-based precision medicine company, acquired The Transplant Pharmacy for an undisclosed amount. This acquisition allows CareDx, Inc. to enhance its medication management portfolio, particularly in the area of organ transplantation. The Transplant Pharmacy specializes in providing transplant services at various locations, delivering personalized patient care that includes online patient portal services and a mobile app for medication management.
Major companies operating in the organ transplant immunosuppressant drugs market include Astellas Pharma Inc., F. Hoffmann-La Roche AG, Novartis AG, Accord Healthcare Limited, GlaxoSmithKline PLC, Pfizer Inc., Sanofi S.A., Alsachim a Shimadzu Group Company, Neovii Pharmaceuticals AG, Zydus Lifesciences Limited, Dr. Reddy's Laboratories Ltd., Lupin Limited, Mylan N.V., Strides Pharma Global Pte Ltd., Asahi Kasei Corporation, Bristol-Myers Squibb Company, Veloxis Pharmaceuticals A/S, Viatris Inc., Janssen Pharmaceuticals Inc., AbbVie Inc., Hansa Biopharma AB, Wockhardt Ltd, Glenmark Pharmaceuticals Ltd., Biocon Ltd., Hikma Pharmaceuticals PLC, Teva Pharmaceutical Industries Ltd., Cipla Ltd., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Intas Pharmaceuticals Limited, Alkem Laboratories Limited, Torrent Pharmaceuticals Limited.
North America was the largest region in the organ transplant immunosuppressant drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the global organ transplant immunosuppressant drugs market report during the forecast period. The regions covered in the organ transplant immunosuppressant drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the organ transplant immunosuppressant drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Organ transplant immunosuppressant drugs are crucial medications employed to curb the immune response in transplant recipients, mitigating the risk of rejection against the transplanted organ.
These drugs primarily fall into several classes calcineurin inhibitors, antiproliferative agents, mTOR inhibitors, steroids, and other miscellaneous classes. Calcineurin, an enzyme pivotal in T-cell activation, prompts the immune system to attack transplanted organs. Calcineurin inhibitors serve to prevent such rejection reactions in patients undergoing organ transplantation. These drugs find extensive use in heart, kidney, liver, lung, pancreas, and other organ transplants, and they are typically dispensed through hospital pharmacies, retail outlets, and online pharmacy platforms.
The organ transplant immunosuppressant drugs market research report is one of a series of new reports that provides organ transplant immunosuppressant drugs market statistics, including organ transplant immunosuppressant drugs industry global market size, regional shares, competitors with an organ transplant immunosuppressant drugs market share, detailed organ transplant immunosuppressant drugs market segments, market trends and opportunities, and any further data you may need to thrive in the organ transplant immunosuppressant drugs industry. This organ transplant immunosuppressant drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The organ transplant immunosuppressant drugs market consists of sales of drugs such asteroid-sparing immunosuppressants, prednisone, antineoplastics, monoclonal antibody drug, and immunosuppressive agents. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Organ Transplant Immunosuppressant Drugs Market Characteristics3. Organ Transplant Immunosuppressant Drugs Market Trends and Strategies4. Organ Transplant Immunosuppressant Drugs Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid and Recovery on the Market32. Global Organ Transplant Immunosuppressant Drugs Market Competitive Benchmarking and Dashboard33. Key Mergers and Acquisitions in the Organ Transplant Immunosuppressant Drugs Market34. Recent Developments in the Organ Transplant Immunosuppressant Drugs Market
5. Global Organ Transplant Immunosuppressant Drugs Growth Analysis and Strategic Analysis Framework
6. Organ Transplant Immunosuppressant Drugs Market Segmentation
7. Organ Transplant Immunosuppressant Drugs Market Regional and Country Analysis
8. Asia-Pacific Organ Transplant Immunosuppressant Drugs Market
9. China Organ Transplant Immunosuppressant Drugs Market
10. India Organ Transplant Immunosuppressant Drugs Market
11. Japan Organ Transplant Immunosuppressant Drugs Market
12. Australia Organ Transplant Immunosuppressant Drugs Market
13. Indonesia Organ Transplant Immunosuppressant Drugs Market
14. South Korea Organ Transplant Immunosuppressant Drugs Market
15. Western Europe Organ Transplant Immunosuppressant Drugs Market
16. UK Organ Transplant Immunosuppressant Drugs Market
17. Germany Organ Transplant Immunosuppressant Drugs Market
18. France Organ Transplant Immunosuppressant Drugs Market
19. Italy Organ Transplant Immunosuppressant Drugs Market
20. Spain Organ Transplant Immunosuppressant Drugs Market
21. Eastern Europe Organ Transplant Immunosuppressant Drugs Market
22. Russia Organ Transplant Immunosuppressant Drugs Market
23. North America Organ Transplant Immunosuppressant Drugs Market
24. USA Organ Transplant Immunosuppressant Drugs Market
25. Canada Organ Transplant Immunosuppressant Drugs Market
26. South America Organ Transplant Immunosuppressant Drugs Market
27. Brazil Organ Transplant Immunosuppressant Drugs Market
28. Middle East Organ Transplant Immunosuppressant Drugs Market
29. Africa Organ Transplant Immunosuppressant Drugs Market
30. Organ Transplant Immunosuppressant Drugs Market Competitive Landscape and Company Profiles
31. Organ Transplant Immunosuppressant Drugs Market Other Major and Innovative Companies
35. Organ Transplant Immunosuppressant Drugs Market High Potential Countries, Segments and Strategies
36. Appendix
Executive Summary
Organ Transplant Immunosuppressant Drugs Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on organ transplant immunosuppressant drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for organ transplant immunosuppressant drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The organ transplant immunosuppressant drugs market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Drug Class: Calcineurin Inhibitors; Antiproliferative Agents; mTOR Inhibitor; Steroids; Others Drug Classes2) By Transplant Type: Heart; Kidney; Liver; Lung; Pancreas; Other Transplant Types
3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
Subsegments:
1) By Calcineurin Inhibitors: Cyclosporine; Tacrolimus2) By Antiproliferative Agents: Azathioprine; Mycophenolate Mofetil; Mycophenolic Acid
3) By MTOR Inhibitor: Sirolimus; Everolimus
4) By Steroids: Prednisone; Methylprednisolone
5) By Other Drug Classes: Costimulation Blockers; Sodium Channel Blockers; Antibody-Based Therapies
Key Companies Mentioned: Astellas Pharma Inc.; F. Hoffmann-La Roche AG; Novartis AG; Accord Healthcare Limited; GlaxoSmithKline PLC
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- Astellas Pharma Inc.
- F. Hoffmann-La Roche AG
- Novartis AG
- Accord Healthcare Limited
- GlaxoSmithKline PLC
- Pfizer Inc.
- Sanofi S.A.
- Alsachim a Shimadzu Group Company
- Neovii Pharmaceuticals AG
- Zydus Lifesciences Limited
- Dr. Reddy's Laboratories Ltd.
- Lupin Limited
- Mylan N.V.
- Strides Pharma Global Pte Ltd.
- Asahi Kasei Corporation
- Bristol-Myers Squibb Company
- Veloxis Pharmaceuticals A/S
- Viatris Inc.
- Janssen Pharmaceuticals Inc.
- AbbVie Inc.
- Hansa Biopharma AB
- Wockhardt Ltd
- Glenmark Pharmaceuticals Ltd.
- Biocon Ltd.
- Hikma Pharmaceuticals PLC
- Teva Pharmaceutical Industries Ltd.
- Cipla Ltd.
- Sun Pharmaceutical Industries Ltd.
- Aurobindo Pharma Limited
- Intas Pharmaceuticals Limited
- Alkem Laboratories Limited
- Torrent Pharmaceuticals Limited
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | February 2025 |
| Forecast Period | 2025 - 2029 |
| Estimated Market Value ( USD | $ 5.52 Billion |
| Forecasted Market Value ( USD | $ 6.61 Billion |
| Compound Annual Growth Rate | 4.6% |
| Regions Covered | Global |
| No. of Companies Mentioned | 32 |
